Agios Pharmaceuticals, Inc. AGIO
29.25 USD -0.43 (-1.45%)
As ofNov 19, 2026, 12:52 PM EST
29.05 Day range 30.35
23.00 52-week range 44.09
- YTD
- +7.46%
- 1 year
- +30.93%
News
benzinga.com Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $35 Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $37 to $35.
benzinga.com HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $62 HC Wainwright & Co. analyst Douglas Tsao maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $55 to $62.
benzinga.com Agios Pharmaceuticals Q3 2026 Earnings Call Transcript Agios Pharmaceuticals (NASDAQ:AGIO) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Agios Pharmaceuticals Q3 EPS $(1.09) Beats $(1.20) Estimate, Sales $55.385M Beat $53.208M Estimate Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.09) per share which beat the analyst consensus estimate of $(1.20) by 9.17 percent. This is a 38.76 percent increase over losses…
benzinga.com Agios Pharmaceuticals Says FDA Extends Mitapivat PDUFA Date For Sickle Cell Disease To February 1, 2027 FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell diseaseFDA classified Agios’ response to the information request as a major…
benzinga.com HC Wainwright & Co. Assumes Agios Pharmaceuticals at Buy, Announces Price Target of $55 HC Wainwright & Co. analyst Douglas Tsao assumes Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy rating and announces Price Target of $55.
